Brief: Celyad Oncology To Discontinue Development Of CYAD-101

Celyad Oncology SA

12/10/2022 06:09

Oct 12 (Reuters) - Celyad Oncology SA  CYAD.BR :
    * CELYAD ONCOLOGY PROVIDES STRATEGIC UPDATE
    * IS INCREASINGLY FOCUSING ON MAXIMIZING ITS VALUABLE
INTELLECTUAL
PROPERTY ESTATE, THROUGH RESEARCH AND DEVELOPMENT EFFORTS WHERE
COMPANY HAS GREATEST EXPERTISE
    * U.S. PATENTS AROUND ALLOGENEIC CAR T THERAPY AND
NKG2D-BASED
THERAPIES PROVIDE AN AVENUE TO DEVELOP INTELLECTUAL PROPERTY
PROGRAMS AND TO PARTNER WITH OUTSIDE PARTIES AROUND LICENSING OF
THESE PATENTS
    * CURRENTLY MAKING PROGRESS IN MULTIPLE DISCOVERY PROGRAMS,
INCLUDING IN DUAL TARGETING CARS WITH NKG2D CAPABILITIES AND AN
UNDISCLOSED TARGET
    * COMPANY HAS DECIDED TO DISCONTINUE DEVELOPMENT OF
CYAD-101, NO
SAFETY CONCERNS LEAD TO DECISION
    * CYAD-211 CLINICAL UPDATES EXPECTED BY YEAR END

Source text for Eikon:  ID:nBw2HsNmZa 
Further company coverage:  CYAD.BR 
 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))